Equities research analysts expect that OpGen, Inc. (NASDAQ:OPGN) will report $810,000.00 in sales for the current quarter, according to Zacks. Two analysts have provided estimates for OpGen’s earnings. The lowest sales estimate is $750,000.00 and the highest is $860,000.00. OpGen reported sales of $1.01 million in the same quarter last year, which would suggest a negative year over year growth rate of 19.8%. The business is scheduled to issue its next earnings results on Thursday, March 22nd.

On average, analysts expect that OpGen will report full-year sales of $810,000.00 for the current fiscal year. For the next financial year, analysts anticipate that the firm will report sales of $3.39 million per share. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover OpGen.

A number of research firms have commented on OPGN. Zacks Investment Research upgraded shares of OpGen from a “hold” rating to a “buy” rating and set a $0.25 price objective for the company in a report on Tuesday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $1.00 price objective on shares of OpGen in a report on Wednesday, November 8th.

Shares of OpGen (NASDAQ OPGN) opened at $0.20 on Friday. The company has a market cap of $11.23 and a PE ratio of -0.39. The company has a quick ratio of 1.13, a current ratio of 1.23 and a debt-to-equity ratio of 0.03. OpGen has a 1-year low of $0.15 and a 1-year high of $1.85.

A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. lifted its position in shares of OpGen, Inc. (NASDAQ:OPGN) by 1.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 342,860 shares of the medical research company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned approximately 1.25% of OpGen worth $219,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 11.83% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/zacks-analysts-expect-opgen-inc-opgn-will-announce-quarterly-sales-of-810000-00/1797075.html.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with Analyst Ratings Network's FREE daily email newsletter.